Intraocular Melanoma Completed Phase 2 Trials for Temozolomide (DB00853)

Also known as: Intraocular melanoma NOS

IndicationStatusPhase
DBCOND0028574 (Intraocular Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00027742Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV MelanomaTreatment
NCT00072345Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV MelanomaTreatment